Your AI-Trained Oncology Knowledge Connection!
Ryan Scott joined MJH Life Sciences in 2021. In addition to writing and editing timely news and article coverage, she manages OncLive's social media accounts; check us out @onclive across platforms such as LinkedIn, Facebook, X, and Instagram! She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: rscott@onclive.com
Sacituzumab govitecan-hziy displayed a manageable safety profile consistent with previous reports in patients with hormone receptor–positive, HER2-negative metastatic breast cancer, irrespective of UGT1A1 status, according to a safety analysis of the phase 3 TROPiCS-02 trial.
Atezolizumab in combination with trastuzumab and vinorelbine generated responses and a tolerable safety profile in patients with HER2-positive, estrogen receptor–negative or ER-positive/PAM50 non-luminal advanced breast cancer, according to data from a prespecified interim analysis of the phase 2 ATREZZO trial.
Susan Bal, MD, discusses the data that supported the FDA approvals of ide-cel and cilta-cel, how the implementation of these agents has shifted how patients with later-line relapsed/refractory multiple myeloma are treated, and the challenges that still need to be addressed with CAR T-cell therapy.
Andrew T. Kuykendall, MD, expands on the rationale for exploring BET inhibition in the treatment of patients with myelofibrosis, details the implications of data from the MANIFEST trial, and discusses other potential targets for novel therapies for myelofibrosis.
Bhavana Pothuri, MD, expands on challenges that still need to be addressed for the treatment of patients with endometrial cancer, highlights potential practice-changing data from the phase 3 NRG-GY018 and RUBY trials, details the evolving role of PARP inhibitors for patients with ovarian cancer, and touches on key emerging data from trials for patients with cervical cancer.
R. Kate Kelley, MD, details the ongoing investigation of RLY-4008 for patients with advanced cholangiocarcinoma harboring FGFR2 fusions or rearrangements, other ongoing investigations in cholangiocarcinoma, and the importance of molecular testing to drive treatment decisions in this population.
Faculty from an OncLive® Institutional Perspectives in Cancer webinar on multiple myeloma summarize the main messages from their presentations.
Shahrzad A. Zamani discusses the research on cancer disparities in patients within the LGBTQI+ population, and how these findings could inform further research and decisions in clinical practice.
Antoinette R. Tan, MD, MHSc, discussed the promise of oral SERDs as they continue to be developed for the treatment of patients with ER-positive, HER2-negative breast cancer, factors that inform treatment decisions following disease progression on a CDK4/6 inhibitor, and the growing role of antibody-drug conjugates across the breast cancer spectrum.
The use of docetaxel and ramucirumab yielded antitumor activity and showcased a manageable safety profile in patients with non–small cell lung cancer who progressed on platinum-based chemotherapy and immune checkpoint inhibitors, according to data from the phase 2 SCORPION study.
The combination of OP-1250 and palbociclib produced a tolerable safety profile and elicited tumor responses and disease stabilization in patients with hormone receptor–positive, HER2-negative metastatic breast cancer.
Michael Basin, MD, discusses the rationale for the preclinical investigation of belzutifan resistance in ccRCC cell lines, the next steps for this research, and the potential implications for combining Hsp70 inhibition with a HIF2α inhibitor.
Olaparib provided consistent clinical benefit in patients with germline BRCA-mutated, HER2-negative metastatic breast cancer, irrespective of estrogen receptor expression level.
John Michael "JM" Bryant, MD, expands on the results of the interim analysis of the single-center, single-arm phase 2 trial for patients with grade group 5 prostate cancer treated with the combination of nivolumab and standard of care.
Mara Koelker, MD, discusses the rationale of evaluating racial differences in QOL for patients with prostate cancer and ways to address these short-term disparities in a real-world setting.
John L. Marshall, MD, discusses the identification of targetable subsets of patients with advanced CRC, unmet needs that remain to be addressed for patients with advanced CRC, and the continued need for a multidisciplinary approach in treating patients across the gastrointestinal cancer spectrum.
Liat Hogen, MD, FRCSC, discussed the potential benefit for cytoreductive surgery in patients with initially unresectable stage IV epithelial ovarian cancer and the implications of findings from this retrospective analysis on future clinical decisions.
Karen S. Anderson, MD, PhD, discusses emerging data and role for CDK4/6 inhibitors in the treatment of patients with hormone receptor–positive, HER2-negative breast cancer, along with the growing use of antibody-drug conjugates across the breast cancer spectrum and updates in triple-negative breast cancer.
Eric A. Singer, MD, discusses the findings from cohort B of KEYNOTE-057 and explains why systemic therapy with pembrolizumab could be beneficial for patients with Bacillus Calmette-Guérin–unresponsive, high-risk, papillary-only non–muscle invasive bladder cancer who hope to avoid radical cystectomy.
Sia Daneshmand, MD, discusses the rationale for investigating TAR-200 for the treatment of patients with Bacillus Calmette-Guérin-unresponsive, high-risk non–muscle-invasive bladder cancer, expands on the preliminary efficacy and safety data from the SunRISe-1 trial, and more.
The combination of gedatolisib and fulvestrant with or without palbociclib is under evaluation in the phase 3 VIKTORIA-1 trial for the treatment of patients with PIK3CA-mutated or wild-type hormone receptor–positive/HER2-negative breast cancer who have previously progressed on first-line therapy.
Manali Bhave, MD, discusses the effect of emerging therapies on the treatment landscape for patients with HR-positive, HER2-negative or -low breast cancer, highlighted her stance on sequencing decisions for these patients, and expanded on the additional work being done to optimize treatment sequencing from a growing list of options.
VT3989, a first-in-class YAP/TEAD inhibitor, showcased durable antitumor activity and tolerability in patients with malignant mesothelioma and other solid tumors harboring NF2 mutations, according to data from a phase 1 trial presented at the 2023 AACR Annual Meeting.
First-line treatment with furmonertinib plus icotinib induced responses in patients with EGFR-mutant non–small cell lung cancer. including those with central nervous system metastases, according to data from an ongoing phase 2 trial.
Overall response rates were similar across subgroups of patients with nonsquamous non–small cell lung cancer for the combinations of dostarlimab-gxly plus chemotherapy and pembrolizumab plus chemotherapy, and responses numerically favored the dostarlimab-based combination in most subgroups, according to a subgroup analysis of the phase 2 PERLA trial.
A long-term post-hoc analysis from the JAVELIN Bladder 100 trial demonstrated that first-line maintenance avelumab elicited similar overall survival and progression-free survival benefits vs best supportive care alone in patients with advanced urothelial carcinoma.
John L. Hays, MD, PhD, discusses the importance of tailoring therapies for patients with CRC who express HER2 or have other actionable targets, the need to develop optimal sequences for local and systemic therapy in CRC, and key updates in hepatocellular carcinoma and pancreatic cancer.
Adjuvant pembrolizumab prolonged disease-free survival and distant metastasis–free survival vs placebo in patients with clear cell renal cell carcinoma at increased risk of recurrence after nephrectomy, irrespective of UCLA Integrated Staging System risk category and disease stage.
Terence Friedlander, MD, discusses the significance of the FDA approval of enfortumab vedotin combined with pembrolizumab for patients with locally advanced or metastatic urothelial carcinoma, and expands on the data from the EV-103/KEYNOTE-869 trial that supported the approval.
R. Lor Randall, MD, FACS, expands on data from a phase 3 trial evaluating the addition of ganitumab to standard-of-care, interval-compressed chemotherapy, the implications of these results, and how the study could help inform future trials exploring other targeted therapies for the treatment of patients with metastatic Ewing sarcoma.
